Dimension Therapeutics’ gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but … – Seeking Alpha
StockNewsUnion |
Dimension Therapeutics' gene therapy candidate for hemophilia B shows treatment benefit in early-stage study but …
Seeking Alpha Thinly traded micro cap Dimension Therapeutics (NASDAQ:DMTX) is off 33% premarket on increased volume in response to its announcement of interim results from a Phase 1/2 clinical trial assessing gene therapy candidate, Orphan Drug-tagged DTX101, … Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Regulation FD Disclosure Is Dimension Therapeutics Inc (DMTX)'s Fuel Running Low? The Stock Reaches Yearly Low Today Form 8-K Dimension Therapeutics, For: Jan 31 |
